Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma

Severe asthma affects an estimated 5–10% of the total asthma patient population [1]. Various demographic factors, such as sex, age, obesity and age of onset, have been associated with asthma disease severity [2, 3], and the efficacy of asthma treatments has previously been found to vary depending on...

Full description

Saved in:

Bibliographic Details
Published in:	The European respiratory journal Vol. 58; no. 4; p. 2004605
Main Authors:	Busse, William W., Paggiaro, Pierluigi, Muñoz, Xavier, Casale, Thomas B., Castro, Mario, Canonica, G. Walter, Douglass, Jo A., Tohda, Yuji, Daizadeh, Nadia, Ortiz, Benjamin, Pandit-Abid, Nami
Format:	Journal Article
Language:	English
Published:	European Respiratory Society 01-10-2021
Subjects:	Agora
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Severe asthma affects an estimated 5–10% of the total asthma patient population [1]. Various demographic factors, such as sex, age, obesity and age of onset, have been associated with asthma disease severity [2, 3], and the efficacy of asthma treatments has previously been found to vary depending on patient demographics [4, 5]. Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlD
Bibliography:	SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Correspondence-1
ISSN:	0903-1936 1399-3003
DOI:	10.1183/13993003.04605-2020